We initially targeted CTLA-4 for checkpoint inhibition given data suggesting that this can facilitate a proinflammatory response to compensate for the relative immunoparalysis conferred by coinhibitory markers during sepsis (66–68). Here, CTLA4 is linked to Sepsis.